Recurrent positive SARS‐CoV‐2: Immune certificate may not be valid

Liu, Tao; Wu, Shuping; Zeng, Guang; Zhou, Fuling; Li, Yirong; Guo, Fangjian; Wang, Xinghuan

doi:10.1002/jmv.26074

Cited by 18 publications

(9 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2). Liu et al 16 found the lowest incidence (7.33%, N = 150), and Li et al 15 found the highest incidence (46.2%, N = 13). The pooled incidence in the peer-reviewed only studies was similar to that of the total studies, i.e., 14.6% (95% CI 11.05-18.09%) with I 2 of 75%.…”

Section: Resultsmentioning

confidence: 95%

“…We observed differences in the pooled estimate incidence for recurrent SARS-CoV-2 RNA positivity based on specimen type. The highest pooled incidence of recurrent positivity was nasopharyngeal only specimens (17.3%), followed by fecal only (16.7%), combined [(oro-/naso-pharyngeal and fecal) 16.1%], oro-/naso-pharyngeal only (13.5%), and oropharyngeal only (7.6%). (Supplementary Table 3).…”

Section: Resultsmentioning

confidence: 97%

See 1 more Smart Citation

Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis

Azam

Sulistiana

Ratnawati³

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Present study aimed to estimate the incidence of recurrent SARS-CoV-2 RNA positivity after recovery from COVID-19 and to determine the factors associated with recurrent positivity. We searched the PubMed, MedRxiv, BioRxiv, the Cochrane Library, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry for studies published to June 12, 2020. Studies were reviewed to determine the risk of bias. A random-effects model was used to pool results. Heterogeneity was assessed using I2. Fourteen studies of 2568 individuals were included. The incidence of recurrent SARS-CoV-2 positivity was 14.8% (95% confidence interval [CI] 11.44–18.19%). The pooled estimate of the interval from disease onset to recurrence was 35.4 days (95% CI 32.65–38.24 days), and from the last negative to the recurrent positive result was 9.8 days (95% CI 7.31–12.22 days). Patients with younger age and a longer initial illness were more likely to experience recurrent SARS-CoV-2 positivity, while patients with diabetes, severe disease, and a low lymphocyte count were less likely to experience. Present study concluded that the incidence of recurrent SARS-CoV-2 positivity was 14.8% suggesting further studies must be conducted to elucidate the possibility of infectious individuals with prolonged or recurrent RNA positivity.

show abstract

Section: Resultsmentioning

confidence: 95%

Section: Resultsmentioning

confidence: 97%

Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis

Azam

Sulistiana

Ratnawati³

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…After reviewing full-text articles, 15 studies were excluded because they reported overlapping cases (N = 6) or irrelevant population (N = 3), there was no information for outcomes of interest (N = 4), and they were studies of mechanisms or modeling (N = 2). The remaining 41 studies were therefore eligible for the final analysis [ 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 ].…”

Section: Resultsmentioning

confidence: 99%

“…It was also possible for the absence of IgM and IgG antibodies, which were capable of connecting to the virus and preventing it from entering the host cell [ 66 ], in the acute and convalescent serum of the reinfected patients [ 67 ]. Although neutralizing antibodies and memory B and T cells again some common human coronaviruses (HCoV) such as HCoV-229E and HCoV-OC43 were also suggested to confer cross-immunity against SARS-CoV-2 [ 68 ], a report based on data on 150 patients showed that the presence of serum IgM and IgG was not significantly associated with a lower rate of disease recurrence (OR = 0.92, 95% CI = 0.27–3.16) [ 69 ].…”

Section: Discussionmentioning

confidence: 99%

Characteristics of COVID-19 Recurrence: A Systematic Review and Meta-Analysis

Hoang

2021

Annals of Global Health

View full text Add to dashboard Cite

Background: Previous studies reported the recurrence of coronavirus disease 2019 (COVID-19) among discharge patients. This study aimed to examine the characteristic of COVID-19 recurrence cases by performing a systematic review and meta-analysis. Methods: A systematic search was performed in PubMed and Embase and gray literature up to September 19, 2020. A random-effects model was applied to obtain the pooled prevalence of disease recurrence among recovered patients and the prevalence of subjects underlying comorbidity among recurrence cases. The other characteristics were calculated based on the summary data of individual studies. Results: A total of 41 studies were included in the final analysis, we have described the epidemiological characteristics of COVID-19 recurrence cases. Of 3,644 patients recovering from COVID-19 and being discharged, an estimate of 15% (95% CI, 12% to 19%) patients was re-positive with SARS-CoV-2 during the follow-up. This proportion was 14% (95% CI, 11% to 17%) for China and 31% (95% CI, 26% to 37%) for Korea. Among recurrence cases, it was estimated 39% (95% CI, 31% to 48%) subjects underlying at least one comorbidity. The estimates for times from disease onset to admission, from admission to discharge, and from discharge to RNA positive conversion were 4.8, 16.4, and 10.4 days, respectively. Conclusion: This study summarized up-to-date evidence from case reports, case series, and observational studies for the characteristic of COVID-19 recurrence cases after discharge. It is recommended to pay attention to follow-up patients after discharge, even if they have been in discharge quarantine.

show abstract

“…The pooled estimate of the incidence of recurrent SARS-CoV-2 positivity was 14.81% (95% CI: 11.44–18.19%) (Figure 2). Liu et al[11] found the lowest incidence (7.33%, N=150), and Li et al[12] found the highest incidence (46.2%, N=13).…”

Section: Resultsmentioning

confidence: 99%

Recurrent SARS-CoV-2 RNA positivity after COVID-19: A systematic review and meta-analysis

Azam

Sulistana

Ratnawati³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Previous studies reported recurrent SARS CoV2 RNA positivity in individuals who had recovered from COVID 19 infections. However, little is known regarding the systematic review of recurrent SARS-CoV-2 RNA positivity. The current study conducted a systematic review and meta-analysis, aimed to estimate the incidence of recurrent SARS CoV 2 RNA positivity after recovery from COVID 19 and to determine the factors associated with recurrent positivity. Methods: We searched the PubMed, MedRxiv, BioRxiv, the Cochrane Library, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry for studies published to June 12, 2020. Studies were reviewed to determine the risk of bias. A random-effects model was used to pool results. Heterogeneity was assessed using I2. Results: Fourteen studies of 2,568 individuals were included. The incidence of recurrent SARS-CoV-2 positivity was 14.81% (95% confidence interval [CI]: 11.44-18.19%). The pooled estimate of the interval from disease onset to recurrence was 35.44 days (95% CI: 32.65-38.24 days), and from the last negative to recurrent positive result was 9.76 days (95% CI: 7.31-12.22 days). Patients with younger age (mean difference [MD]=-2.27, 95% CI: -2.95 to -1.80) and a longer initial illness (MD=8.24 days; 95% CI: 7.54-8.95; I2=98.9%) were more likely to experience recurrent SARS-CoV-2 positivity, while patients with diabetes (RR=0.52; 95% CI: 0.30-0.90; I2=53%), severe disease (RR=0.54; 95% CI: 0.35-0.84; I2=70%), and a low lymphocyte count (RR=0.58; 95% CI: 0.39-0.86; I2=48%) were less likely to experience recurrent SARS CoV 2 positivity. Conclusions: The incidence of recurrent SARS CoV 2 positivity was 14.81%. The estimated interval from disease onset to repeat positivity was 35.44 days, and the estimated interval from the last negative result to recurrent positive result duration was 9.76 days.

show abstract

Recurrent positive SARS‐CoV‐2: Immune certificate may not be valid

Cited by 18 publications

References 6 publications

Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis

Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis

Characteristics of COVID-19 Recurrence: A Systematic Review and Meta-Analysis

Recurrent SARS-CoV-2 RNA positivity after COVID-19: A systematic review and meta-analysis

Contact Info

Product

Resources

About